EXHIBIT 99.1

PRESS RELEASE


             XTRANA ANNOUNCES THE SALE OF ITS HEMOSTASIS OPERATIONS

     BROOMFIELD, Colo--Nov. 12, 2001--Xtrana, Inc. (OTCBB:XTRN - news) announced
today that it has entered into a definitive Asset Purchase Agreement with
Trinity Biotech plc, (NASDAQ:TRIB - news) in which Trinity has agreed to
purchase substantially all of the assets of Xtrana's Hemostasis business for
$6,250,000. Completion of the sale is subject to a number of closing conditions,
including the approval of a majority of Xtrana's stockholders to be solicited at
a Special Meeting of Stockholders scheduled for December of this year.

     Under the terms of the Asset Purchase Agreement, Trinity will purchase
certain assets and assume certain liabilities of Xtrana's Hemostasis business.
These assets include the operations located in Ventura, California, and the
Company's wholly owned Swedish subsidiary, Biopool AB. The total consideration
to be paid to Xtrana of $6,250,000 will consist of cash and notes as follows:
(a) $3,658,500 in cash at closing; (b) a note in the amount of $855,200 due one
year from the closing date; (c) a note in the amount of $1,166,200 due two years
from the closing date; and (d) a note in the amount of $570,100 due three years
from the closing date. The notes will carry interest at a rate of 5% per annum
and will be secured by a second position on all U.S. assets of Trinity.

     Tim Dahltorp, Xtrana's chief executive officer, commented, "The sale of the
Hemostasis business to Trinity is consistent with the strategic direction of the
Company subsequent to our merger with Xtrana just over a year ago. This
transaction will allow the Company to exit the Hemostasis business at a fair
valuation and redirect all of our resources into the development and
commercialization of our proprietary technologies in the fields of genomics and
nucleic acid diagnostics. The proceeds from the sale will provide Xtrana with a
very solid financial footing from which we hope to build a strong business based
on our innovative intellectual property portfolio."

     Trinity Biotech develops, manufactures and markets over 200 diagnostic
products for the point-of-care, self-testing and clinical laboratory segments of
the diagnostic market. Trinity Biotech sells worldwide in over 80 countries
through its own sales force and a network of international distributors and
strategic partners. For further information, please see the Company's website:
www.trinitybiotech.com.

     Xtrana's mission is to simplify the analysis of DNA/RNA, so that nucleic
acid based detection systems can be utilized in point-of-care, point-of-service
applications. The proprietary assays developed by Xtrana are designed to be easy
to use outside of a traditional


                                     Page 1



molecular biology laboratory at a cost per test that is competitive with
existing rapid test technologies. These diagnostic tests are intended for use in
drug discovery, detection of environmental and food contaminants, forensics and
identity testing, human and animal diseases, genetic predisposition to disease,
and other applications. The Company's first commercial nucleic acid product is
Xtra Amp(TM), DNA or RNA extraction kits that enable high throughput extraction
in as little as 3 minutes, versus competing technologies that can take 30
minutes to 3 hours. The Company also develops, manufactures, and markets a full
range of test kits to assess and diagnose disorders of blood coagulation,
thrombotic risk factors, fibrinolysis, platelet function, and the vascular
system under the Biopool(R) label. To learn more about Xtrana, visit the
Company's website at www.xtrana.com.

     This Press Release contains forward-looking statements (identified by the
words "estimate," "anticipate," "expect," "believe," and similar expressions),
which are based upon management's current expectations and speak only as of the
date made. These forward-looking statements are subject to risks, uncertainties
and factors that could cause actual results to differ materially from the
results anticipated in the forward-looking statements and include, but are not
limited to, competitors' pricing strategies and technological innovations,
changes in health care and government regulations, litigation claims, foreign
currency fluctuation, product acceptance, as well as other factors discussed in
the Company's last Report on Form 10-KSB.

Contact:
       Xtrana, Inc.
      Timothy Dahltorp, 303/466-4424
      or
      Carol Hill, 805/654-0643
      www.xtrana.com


                                     Page 2